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ABSTRACT
Objective: Compliance with guidelines is increasingly
used to benchmark the quality of hospital care,
however, very little is known on patients admitted with
acute coronary syndromes (ACS) and treated
palliatively. This study aimed to evaluate the baseline
characteristics and outcomes of these patients.
Design: Prospective cohort study.
Setting: Eighty-two Swiss hospitals enrolled patients
from 1997 to 2014.
Participants: All patients with ACS enrolled in the AMIS
Plus registry (n=45 091) were analysed according to
three treatment groups: palliative treatment, defined as
use of aspirin and analgesics only and no reperfusion;
conservative treatment, defined as any treatment
including antithrombotics or anticoagulants, heparins,
P2Y12 inhibitors, GPIIb/IIIa but no pharmacological or
mechanical reperfusion; and reperfusion treatment
(thrombolysis and/or percutaneous coronary intervention
during initial hospitalisation). The primary outcome
measure was in-hospital mortality and the secondary
measure was 1-year mortality.
Results: Of the patients, 1485 (3.3%) were palliatively
treated, 11 119 (24.7%) were conservatively treated and
32 487 (72.0%) underwent reperfusion therapy. In 1997,
6% of all patients were treated palliatively and this
continuously decreased to 2% in 2013. Baseline
characteristics of palliative patients differed in
comparison with conservatively treated and reperfusion
patients in age, gender and comorbidities (all p<0.001).
These patients had more in-hospital complications such
as postadmission onset of cardiogenic shock (15.6% vs
5.2%; p<0.001), stroke (1.8% vs 0.8%; p=0.001) and a
higher in-hospital mortality (25.8% vs 5.6%; p<0.001).
The subgroup of patients followed 1 year after discharge
(n=8316) had a higher rate of reinfarction (9.2% vs
3.4%; p=0.003) and mortality (14.0% vs 3.5%;
p<0.001).
Conclusions: Patients with ACS treated palliatively were
older, sicker, with more heart failure at admission and
very high in-hospital mortality. While refraining from
more active therapy may often constitute the most
humane and appropriate approach, we think it is
important to also evaluate these patients and include
them in registries and outcome evaluations.
Clinical trial number: ClinicalTrials.gov Identifier:
NCT01 305 785.
INTRODUCTION
Guideline recommended strategies are
derived from prospective randomised trials
and expert consensus. This may result in bias
since the therapies are only studied in patients
who consent and do not have exclusion cri-
teria. Thus, very little is known on an import-
ant subgroup of patients who at the time of
admission for various reasons received
restricted or palliative treatment only. Reasons
for withholding comprehensive and/or inva-
sive therapy may be a very limited life expect-
ancy, advanced age or severe comorbidity.
These patients are not represented in
Strengths and limitations of this study
▪ This is the first study presenting characteristics
and outcomes of a large cohort of patients
admitted for acute coronary syndrome (ACS) and
treated only palliatively. It compares the differ-
ences in baseline characteristics and outcomes
in hospital and 1 year after discharge of these
patients with patients treated conservatively or
with reperfusion therapy.
▪ Whereas it may often be completely appropriate
to provide restrictive and palliative care only for
elderly patients with very poor prognosis, this
study shows a much larger grey zone of
decision-making.
▪ With this study, it was not possible to find evi-
dence of the exact reasons for withholding active
therapy by only treating patients palliatively.
▪ This study showed that an international consen-
sus should be reached on whether such patients
should be included in the overall evaluation of
patients with ACS outcomes.
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prospective trials and often not included in registries.
They are a poorly deﬁned group in terms of presentation
characteristics and outcome, but they might have a pro-
found inﬂuence on outcome statistics, benchmarking and
resource utilisation.
Since 1997, we have followed diagnostic and treatment
strategies in a long-term nationally based registry in
which all patients are included once a hospital decides
to collaborate for a deﬁned period of time. The present
details of the registry and participants have been
described recently.1–3
Patients were assigned to one of three groups accord-
ing to the therapy received. We present characteristics
and outcomes of a large cohort of patients admitted to
Swiss hospitals with acute coronary syndrome (ACS) who
received primary palliative treatment.
METHODS
The AMIS Plus project is an ongoing nationwide pro-
spective registry of patients with ACS admitted to hospi-
tals in Switzerland, supported by the Swiss Societies of
Cardiology, Internal Medicine and Intensive Care
Medicine. It was founded in 1997 with the goal to under-
stand the transfer, use and practicability of knowledge
gained from randomised trials and to generate data for
the planning of subsequent prospective and randomised
studies. Details have been previously published.1 Of 106
hospitals treating ACS in Switzerland, 82 temporarily or
continuously enrolled patients in AMIS Plus.
Participating centres, ranging from community institu-
tions to large tertiary facilities, provide blinded data for
each patient through standardised internet-based or
paper-based questionnaires. Participating centres are
strongly encouraged to enrol all patients fulﬁlling the
inclusion criteria to avoid selection bias. Hospital data are
provided and completed by the treating physician or a
trained study nurse. All data are checked for complete-
ness, plausibility and consistency by the AMIS Plus Data
Centre in the Epidemiology, Biostatistics and Prevention
Institute at the University of Zurich, and treating physi-
cians or study nurses are queried when necessary.
Centres are randomly audited and the quality of data
checked by the Clinical Trials Unit on an annual basis
since 2011.
In this study, patients with ACS were divided into
groups according to the therapy received during the
initial hospitalisation: palliative treatment, deﬁned as use
of aspirin and analgesics only, without the use of any
other antithrombotics, anticoagulants, heparins, P2Y12
Table 1 Baseline characteristics of patients with ACS according to treatment (N=45 091)
Palliative Conservative Reperfusion
p Value
palliative
vs others
Number of patients 1485 (3.3%) 11 119 (24.7%) 32 487 (72.0%)
Sex, male (%) 867 (58.4) 7113 (64.0) 24 844 (76.5) <0.001
Age in years, mean (SD) 76.7 (12.3) 72.3 (12.9) 63.5 (12.4) <0.001
Delay median (IQR) 305 min (120,
984 min)
350 min (135,
1005 min)
209 min
(105 540 min)
<0.001
Resuscitation prior to admission 84/1465 (5.7) 1388/10 992 (3.5) 1708/32 065 (5.3) 0.14
Symptoms at admission
Pain (%) 930/1363 (68.2) 8584/10 674 (80.4) 27 415/30 911 (88.7) <0.001
Dyspnoea (%) 646/1266 (51.0) 4014/10 138 (39.6) 7034/28 607 (24.6) <0.001
Atrial fibrillation 228/1205 (18.9) 784/8272 (9.5) 996/29 444 (3.4) <0.001
STEMI (%) 585 (39.4) 4578 (41.2) 20 393 (62.8) <0.001
Killip classes 3/4 (%) 266/1457 (18.3) 1182/10 971 (10.8) 1780/32 057 (5.6) <0.001
Hypertension (%) 984/1353 (72.7) 7046/10 620 (66.3) 17 576/30 931 (56.8) <0.001
Diabetes (%) 420/1372 (30.6) 2795/10 753 (26.0) 5599/31 234 (17.9) <0.001
Dyslipidaemia (%) 576/1124 (51.2) 5194/9642 (53.9) 17 237/29 302 (58.8) <0.001
Current smoker (%) 255/1210 (21.1) 2779/10 123 (27.5) 12 817/30 069 (42.6) <0.001
Obesity (BMI>30) (%) 185/983 (18.8) 1559/8413 (18.5) 5786/27 653 (20.9) <0.001
Coronary artery disease (%) 675/1334 (50.6) 460/9658 (47.8) 9980/30 832 (32.4) <0.001
Heart failure (%) 145/1061 (13.7) 535/6692 (8.0) 538/26 742 (2.0) <0.001
Cerebrovascular disease (%) 150/1062 (14.1) 710/6741 (10.5) 1237/27 504 (4.5) <0.001
Hemiplegia (%) 23/1061 (2.2) 103/6692 (1.5) 108/26 742 (0.4) <0.001
Dementia (%) 87/1061 (8.2) 375/6692 (5.6) 187/26 742 (0.7) <0.001
Chronic lung disease (%) 121/1062 (11.4) 696/6741 (10.3) 1280/27 504 (4.7) <0.001
Moderate to severe liver disease (%) 22/1062 (2.1) 63/6741 (0.9) 118/27 310 (0.4) <0.001
Moderate to severe renal disease (%) 223/1062 (21.0) 1013/6741 (15.0) 1213/27 504 (4.4) <0.001
Cancer disease (%) 120/1062 (11.3) 572/6700 (8.5) 1331/26 794 (5.0) <0.001
Charlson Comorbidity Index >1 (%) 577/1061 (54.4) 2791/6692 (41.7) 4901/26 742 (18.3) <0.001
ACS, acute coronary syndrome; BMI, body mass index; IQR, interquartile range; STEMI, ST-elevation myocardial infarction.
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inhibitors, GPIIb/IIIa inhibitors and no pharmacological
or mechanical reperfusion; conservative treatment,
deﬁned as any treatment including antithrombotics or
anticoagulants, heparins, P2Y12 inhibitors (clopidogrel,
prasugrel or ticagrelor), GPIIb/IIIa but no pharmaco-
logical or mechanical reperfusion; and reperfusion treat-
ment, including thrombolysis and/or percutaneous
coronary intervention (PCI).
Comorbidities of the patients were assessed using the
weighted Charlson Index.4 5 Risk factors were documen-
ted in the patient’s medical history: dyslipidaemia, arter-
ial hypertension and diabetes were assigned if the
patient had been previously treated and/or diagnosed
by a physician. Documentation of the risk factors pro-
vided by the local physicians was accepted as stated.
Patients were deﬁned as obese if the body mass index
was ≥30 kg/m2 and as smokers if the patient was a
current smoker at the time of the cardiovascular event.
For the present analysis, the primary outcome
measure was in-hospital mortality and the secondary
outcome measure was 1-year mortality after discharge.
Additionally, the major adverse cardiac and cerebrovas-
cular events in-hospital (MACCE—composite end point
of reinfarction, stroke and/or death) and adverse
cardiac and cerebrovascular events during follow-up
(MACCE—composite end point of reinfarction, stroke,
any reinterventions and/or death) were assessed.
Patient selection
The present analysis included all patients with ACS
enrolled in AMIS Plus between January 1997 and April
2014. ACS included acute myocardial infarction (AMI),
deﬁned according to the universal deﬁnitions of MI by
characteristic symptoms and/or ECG changes and
cardiac marker elevation (either creatine kinase MB frac-
tion at least twice the upper limit of normal or troponin
I or T above individual hospital cut-off levels for MI),
and unstable angina (symptoms or ECG changes com-
patible with ACS and cardiac marker levels lower than
cut-off or normal levels).6 7 Classiﬁcation of ST-elevation
myocardial infarction (STEMI) included evidence of
AMI as above and ST-segment elevation and/or new left
bundle branch block on the initial ECG. Non-STEMI
(NSTEMI) included patients with ischaemic symptoms,
ST-segment depression or T-wave abnormalities in the
absence of ST elevation on the initial ECG.
Since 2006, patients from 59 centres were asked for
written consent to a telephone follow-up contact 12 months
after discharge.
Statistical analysis
Continuous variables are expressed as means ±1 SD or
medians with IQR and were compared between groups
using the Mann-Whitney U test. Categorical data are pre-
sented as percentages and compared between groups using
Pearson’s χ2 test. The Breslow-Day test of homogeneity of
the OR was used to identify subgroups of patients with a
particularly high reduction of palliative treatment between
time periods. Linear regression was used to analyse trends
in age over time and differences between trends of patients
treated palliatively and those treated otherwise. Two-sided
p Values less than 0.05 were considered statistically signiﬁ-
cant. All analyses were performed using IBM SPSS Statistics
(V.22, Armonk, New York: IBM Corp.)
RESULTS
Between January 1997 and April 2014, 45 279 patients
with ACS from 82 Swiss hospitals were enrolled in the
AMIS Plus registry. The data on the therapies received
were missing for 188 (0.4%) patients. Therefore, com-
plete data were available from 45 091 patients. Among
these patients, 72% underwent reperfusion, 24.7% were
treated conservatively and 3.3% palliatively.
The baseline characteristics according to therapy
received during the index hospitalisation are shown in
table 1.
The patients with ACS treated palliatively differed in
all baseline characteristics from the patients treated con-
servatively as well as the patients who received thrombo-
lytic therapy or underwent PCI. They were older,
predominantly women, with more risk factors such as
hypertension, and suffered more frequently from dia-
betes, heart failure, cerebrovascular diseases, renal
Figure 1 Temporal trends of treatments, 1997–2014.
Figure 2 Palliatively treated patients with acute coronary
syndrome (ACS) according to age categories.
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Table 2 Trends in baseline characteristics of patients with ACS according to treatment (N=45 091)
Palliative (n=1485) Conservative (n=11 119) Reperfusion (n=32 487)
1997–
2001
2002–
2005
2006–
2009
2010–
2013
P for
trends
P for
difference in
trends vs
reperfusion
1997–
2001
2002–
2005
2006–
2009
2010–
2013
P for
trends
P for
difference in
trends vs
reperfusion
1997–
2001
2002–
2005
2006–
2009
2010–
2013
P for
trends
Number of
patients
414 416 382 273 4337 2629 2277 1876 4398 8411 9742 9936
Males 65.5 56.3 52.6 59.0 0.018 0.003 67.6 61.4 60.3 63.8 <0.001 <0.001 76.6 76.9 76.6 75.6 0.19
Age in years,
mean (SD)
78.8 (12) 77.8 (12) 80.6 (11) 75.5 (13) <0.001 <0.001 68.9 (13) 74.6 (12) 75.8 (13) 73.1 (13) <0.001 <0.001 62.2 (12) 62.9 (12) 63.5 (12) 64.7 (13) <0.001
Resuscitation
prior to
admission
8.7 6.1 3.1 4.4 0.002 0.011 5.2 2.4 2.0 3.1 <0.001 <0.001 5.9 4.4 5.2 6.0 0.019
Symptoms at admission
Pain 81.6 57.8 66.3 67.3 <0.001 <0.001 87.4 72.5 76.4 80.5 <0.001 <0.001 93.2 78.3 90.3 94.4 <0.001
Dyspnoea 54.9 45.7 54.5 49.4 0.68 <0.001 31.6 41.2 46.1 47.1 <0.001 <0.001 21.3 17.2 26.4 31.6 <0.001
Atrial fibrillation 18.8 18.6 19.4 18.8 0.93 0.50 7.9 10.1 10.4 8.9 0.40 0.001 3.4 3.1 3.1 4.0 0.005
STEMI 51.0 41.1 32.2 29.3 <0.001 0.083 48.6 39.4 35.7 33.0 <0.001 <0.001 78.8 63.5 59.5 58.2 <0.001
Killip classes 3/4 22.3 17.8 16.4 15.6 0.019 0.002 10.0 12.0 11.1 10.3 0.53 <0.001 5.3 4.1 5.7 6.8 <0.001
Hypertension 62.0 71.5 81.3 79.4 <0.001 0.033 55.0 70.4 76.7 75.0 <0.001 <0.001 47.4 54.5 59.5 60.4 <0.001
Diabetes 27.9 32.4 34.2 27.2 0.75 0.13 23.0 28.6 29.0 25.8 <0.001 0.001 16.6 17.8 17.7 18.9 0.002
Dyslipidaemia 47.2 51.6 48.9 60.1 0.013 0.011 50.7 57.2 52.7 58.4 <0.001 <0.001 57.8 64.3 53.9 59.3 0.001
Current smoker 27.6 17.2 14.7 25.1 0.088 0.001 33.0 22.9 22.7 26.1 <0.001 <0.001 45.6 43.7 41.8 41.6 <0.001
Obesity (BMI>30) 15.9 18.8 18.8 21.8 0.16 0.98 19.0 16.9 18.6 19.9 0.46 0.009 17.8 19.8 21.1 22.8 <0.001
CAD 56.8 52.4 50.7 40.2 <0.001 0.068 46.6 51.6 51.0 40.4 0.003 <0.001 34.9 32.4 34.3 29.6 <0.001
Heart failure 23.5 15.9 14.6 7.8 0.001 0.039 12.4 9.3 8.1 5.7 <0.001 0.030 3.1 2.3 1.8 2.0 0.083
Cerebrovascular
disease
17.6 13.4 14.3 14.5 0.87 0.74 8.8 11.6 10.0 9.9 0.16 0.049 5.5 4.5 4.0 5.0 0.12
Dementia 5.9 6.6 9.4 9.3 0.14 0.47 2.1 5.1 6.2 5.9 0.050 0.008 1.2 0.5 0.6 0.7 0.004
Lung disease 14.7 14.1 8.3 11.2 0.12 0.13 16.6 10.8 10.0 9.4 0.014 0.47 9.2 4.7 4.4 4.7 0.44
Renal disease 11.8 17.4 24.8 22.3 0.034 0.16 11.4 12.0 18.1 15.7 <0.001 <0.001 2.8 3.6 4.1 5.4 <0.001
Cancer disease 11.8 10.6 12.4 10.8 0.91 0.25 5.7 9.0 8.5 8.3 0.81 0.001 7.1 4.5 4.3 6.0 <0.001
CCI>1 55.9 54.5 57.3 50.0 0.33 0.020 39.4 41.5 44.2 39.1 0.35 <0.001 23.4 17.7 16.9 20.1 0.001
Age in mean (SD), all other results in percentage.
ACS, acute coronary syndrome; BMI, body mass index; CAD, coronary artery disease; CCI, Charlson comorbidity Index; STEMI, ST-elevation myocardial infarction.
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disease and dementia. Patients with ACS treated pallia-
tively more frequently presented with atypical symptoms,
less pain, dyspnoea, atrial ﬁbrillation, NSTEMI and a
higher Killip class.
Seventy-two per cent of all patients with ACS treated
with reperfusion, 45% of all patients treated palliatively
and 45% of all those treated conservatively were admit-
ted to hospitals with catheter laboratory facilities. For
patients treated palliatively, the delay between symptom
onset and admission was much longer than the reperfu-
sion group but shorter than the conservative group.
Furthermore, more than one-third of the patients
treated palliatively (36.3%) were on anticoagulants
before admission in comparison to those treated conser-
vatively (6.4%) and those who underwent reperfusion
(4.2%).
The percentage of patients with ACS treated without
reperfusion continuously decreased between 1997 and
2013. Conservative treatment dropped from 53.3% to
10.3% and palliative treatment from 6% to 2% (ﬁgure 1).
The percentage of patients with ACS who were palliatively
treated increased with increased age (ﬁgure 2).
Comparison of the two periods (1997–2005 and 2006–
2014) showed a signiﬁcant decrease in the use of pallia-
tive therapy in patients with ACS, particularly in patients
admitted with Killip class >2, from 11% to 5.9% (p for
the test of homogeneity of the OR was 0.028). The same
trend was seen for patients 75 years of age and younger,
dropping from 2.2% to 1.1% (p for the test of homo-
geneity of the OR was <0.001).
Trend analyses per quartile of time showed more
females and patients with moderate to severe renal dis-
eases received palliative treatment, but less resuscitated
patients, less patients with typical symptoms, less patients
with coronary artery disease and heart failure and less
patients who presented with STEMI or acute decompen-
sation (table 2). Additionally, comparisons of the tem-
poral trends of patients treated palliatively and those
who underwent reperfusion showed signiﬁcant differ-
ences in the trends of gender, age, resuscitation, typical
symptoms, Killip classes above 2, dyslipidaemia and
smoking, as well as heart failure and comorbidities
(table 2).
Patients treated palliatively compared with patients
treated with antiplatelets and/or reperfusion were at
greater risk of developing cardiogenic shock during hospi-
talisation (16% vs 5%; p<0.001) and stroke (2% vs 1%;
p=0.001), while bleeding (2.0% vs 2.6%; p=0.36) and rein-
farction in-hospital were similar (2.3% vs 1.7%; p=0.18).
Crude in-hospital mortality was 25.8% in the palliative
group compared with 5.6% for the others (p<0.001) and
MACCE (27.4% vs 7.2%; p<0.001; ﬁgure 3). The median
length of stay was 9 days (IQR 5–15 days) for the pallia-
tively treated, 8 days (IQR 4–13 days) for the conservatively
treated and 5 days (IQR 2–9 days) for the reperfusion
patients (p<0.001). Of the palliatively treated patients who
survived hospital stay (n=1102), 225 (20.4%) were dis-
charged home with homecare assistance or transferred to
a retirement or nursing home compared with 10.4% of
conservatively treated patients (1005/9841) and 1.5%
(464/31 318) of patients who underwent reperfusion.
In-hospital mortality decreased signiﬁcantly between
1997 and 2013 in the groups of patients treated pallia-
tively or with reperfusion, but not in those treated con-
servatively (table 3).
Since 2006, a subgroup of patients with ACS was fol-
lowed 1 year after discharge. From a total of 22 926
patients who could have possibly been included in the
follow-up, 10 770 (47%) were asked to take part. Of
these patients, 1912 (17.8%) refused their consent
leaving 8858 patients available for follow-up. The
follow-up interview was consequently carried out with
8316 patients: 143 (1.7%) patients had been treated pal-
liatively, 1244 (15%) conservatively and 6929 (83.3%)
had received reperfusion treatment during the index
hospitalisation. The outcomes of these patients 1 year
after discharge are shown in ﬁgure 4.
Patients admitted for ACS and treated palliatively suf-
fered reinfarction (9.2% vs 3.4% in others; p=0.003)
more frequently and died more often during the ﬁrst
year after discharge (14.0% vs 3.5%; p<0.001).
There were no signiﬁcant differences in mortality
1 year after discharge over time across the three treat-
ment groups (table 4).
DISCUSSION
This study provides evidence that the population which
received palliative therapy is older and sicker when com-
pared with patients who underwent conservative or
reperfusion treatment and the percentage of palliatively
treated patients increased with age. Adding days and
weeks to a life is not the only goal but to add quality of
Figure 3 In-hospital complications and outcomes according
to therapies received during the index hospitalisation.
Cardiogenic shock—developing during hospitalisation.
MACCE—major adverse cardiac and cerebrovascular events
in-hospital—composite end point of reinfarction, stroke or
death.
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life to this time. The study shows that these questions
are addressed individually. Owing to the substantial lack
of studies on this issue, it is difﬁcult to compare these
results with other situations. It is beyond the scope of
this study and manuscript to analyse why a palliative
option was chosen. Age may at least in part explain the
restrictive treatment decision. A former analysis showed
that elderly patients admitted for ACS received fewer
guideline-recommended medical and interventional
therapies.8 Whereas a higher proportion of patients with
malignant disease is to be expected in the palliative
treated group, the higher prevalence of heart failure
should be interpreted more cautiously, although a pallia-
tive care for patients with advanced heart failure is well
established.9 Only patients presenting with cardiogenic
shock may be considered for restrictive end-of-life care
in connection with other unfavourable characteristics.
Our data, however, show a substantial number of
patients who were initially stable on admission but devel-
oped shock while receiving palliative treatment. This,
and the relatively high survival rate after 1 year for the
group as a whole, may be indicators for undertreatment
in certain subgroups. At least for the long-term survivors,
the restrictive treatment decision should be questioned
as they have a more complicated follow-up with more
reinfarctions and rehospitalisations.
Over time the population offered palliative treatment
only has decreased and was smaller in tertiary care
centres. This may point to non-homogenous criteria for
treatment decisions which may have changed over time
given the increasing age and increasing comorbidities of
the whole infarct population. Whereas it may often be
completely appropriate to provide restrictive and
Figure 4 Outcome of patients with ACS 1 year after
discharge according to therapy received. Any reintervention
included any diagnostic (coronary angiography) or therapeutic
intervention, such as percutaneous coronary intervention,
implantation of pacemaker, bypass surgery, etc. MACCE
during follow-up, major adverse cardiac and cerebrovascular
events—composite end point of reinfarction, stroke, any
reinterventions and/or death; ACS, acute coronary syndrome.
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palliative care only for elderly patients with a very poor
prognosis, our analysis shows a much larger grey zone of
decision-making. This warrants further investigation.
To the best our knowledge, there are no systematic
data available on patients with ACS who were not given
active therapy for whatever reason. There are few case
reports with regard to treatment of patients with MI and
concomitant severe cancer diseases.10 11 Fenning et al12
used two prognostic tools (Golden Standards Framework
and GRACE Score) to identify patients with ACS
approaching end of life and who were therefore eligible
for palliative care. The patients with ACS identiﬁed as
requiring end-of-life care were older, had more
comorbidities, were more likely to be readmitted during
follow-up and had higher mortality than those who did
not meet these criteria. This is in accordance with our
results, which showed that palliatively treated patients
suffered reinfarction more frequently during the 1 year
period after discharge.
This raises the question of whether an effort is neces-
sary to improve compliance by also strictly adhering to
guidelines for patients where analgesic therapy only
would be the most humane approach. The second ques-
tion is how these palliative patients impact the quality
control and benchmarking processes. According to the
results of this study, the overall crude in-hospital mortal-
ity of all patients with ACS during the past 17 years was
6.3%, but after exclusion of the patients treated pallia-
tively this was signiﬁcantly lower with a mortality rate of
5.6%.
Limitations
An important limitation of our study is the lack of evi-
dence for the exact reasons to withhold active therapy
and to treat palliatively only. We did not analyse the
reasons for choosing ‘palliative care’ as the initial strat-
egy and thereby withholding prognostic favourable treat-
ment options to these patients; nor do we have the
means to do this at random. Analysis of such decision-
making under time pressure involving medical perspec-
tives (age, comorbidity) and patient’s wishes and their
quality of life equally is beyond the scope of an infarc-
tion registry, and we accept that there are good reasons
for deciding on palliative treatment for some patients.
However, it would be almost impossible to gain reli-
able data on decision-making in the context of a
national registry. Furthermore, some misclassiﬁcations
cannot be excluded due to the fact that some palliatively
treated patients died before they could be treated
invasively.
Our study should also be interpreted in the context of
the following limitations: the weaknesses of AMIS Plus
are common to all registries. Participation in the AMIS
Plus registry is voluntary; the number of hospitals varied
over the years and this might have caused an unrecog-
nised exclusion bias in patients treated palliatively.
However, the large number of patients and the long-
lasting continuous collection of data involving more
than 75% of Swiss hospitals treating patients with ACS
enable analysis of the observed data. Data quality was
checked by external audits.
CONCLUSIONS
Patients with ACS treated palliatively were older, sicker,
with more heart failure at admission and very high
in-hospital mortality. Changes of treatment decisions
over time and the proportion of patients surviving 1 year
suggest in part non-homogenous and potentially ques-
tionable decision criteria. While refraining from more
active therapy may be the most humane and appropriate
approach in many patients, in others it represents under
treatment. In any case, this patient group warrants
further study and should be included in outcome statis-
tics and registries.
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